Streptococcus pneumoniae remains an important cause of pneumonia and invasive bacterial disease, primarily meningitis and sepsis. The greatest burden of disease occurs in low-and middle-income countries, and the risk of serious pneumococcal disease peaks at the extreme ages of life. Young children are at highest risk, but older adults and people with immuno-compromising conditions also suffer high rates of pneumococcal disease.
The Sabin Vaccine Institute works to extend the benefits of immunization to all people by enabling vaccine access and uptake. Sabin brings together national government officials, policy makers, immunization specialists, researchers and advocates to supply decision makers with the data and expertise they need to make evidence-based decisions on vaccines. Our work includes a number of diseases, including:
Vaccine introduction, policy and financing are complex issues, and countries must achieve ambitious immunization targets with limited available resources. To make informed decisions for the health of their people, decision makers need accurate, up-to-date information to identify vulnerable populations, assess burden of disease, evaluate vaccine efficacy and cost-effectiveness, and measure the efficiency of immunization programs.